Resmetirom

Resmetirom
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration	Oral
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Resmetirom is a novel, orally administered, liver-directed, selective thyroid hormone receptor-β (THR-β) agonist. It is primarily being investigated for the treatment of non-alcoholic steatohepatitis (NASH) and dyslipidemia.

Mechanism of Action

Resmetirom functions by selectively activating the thyroid hormone receptor-β (THR-β) in the liver. This receptor is involved in the regulation of lipid metabolism, cholesterol homeostasis, and energy expenditure. By targeting THR-β, resmetirom aims to reduce liver fat content, improve liver function, and decrease levels of circulating lipids such as low-density lipoprotein (LDL) cholesterol and triglycerides.

Pharmacokinetics

Resmetirom is administered orally and is designed to have a high degree of liver selectivity, minimizing systemic exposure and potential off-target effects. The drug undergoes hepatic metabolism, and its elimination half-life allows for once-daily dosing. The specific metabolic pathways and excretion routes are subjects of ongoing research.

Clinical Development

Resmetirom is currently in advanced stages of clinical trials for the treatment of NASH, a progressive liver disease characterized by steatosis, inflammation, and fibrosis. NASH can lead to cirrhosis and hepatocellular carcinoma. Resmetirom has shown promise in reducing liver fat and improving liver histology in clinical studies.

Non-Alcoholic Steatohepatitis (NASH)

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) and is associated with metabolic syndrome, obesity, and type 2 diabetes mellitus. Current treatment options are limited, and resmetirom represents a potential therapeutic advancement by addressing the underlying metabolic dysfunctions.

Dyslipidemia

Dyslipidemia, characterized by abnormal lipid levels in the blood, is a major risk factor for cardiovascular disease. Resmetirom's ability to lower LDL cholesterol and triglycerides makes it a candidate for managing dyslipidemia, particularly in patients with concurrent NASH.

Safety and Tolerability

In clinical trials, resmetirom has been generally well-tolerated. Common adverse effects include mild gastrointestinal symptoms, such as nausea and diarrhea. The liver-selective action of resmetirom is intended to reduce the risk of systemic side effects typically associated with thyroid hormone therapies.

Future Directions

Ongoing research is focused on further elucidating the long-term efficacy and safety of resmetirom in larger and more diverse patient populations. Additionally, studies are exploring its potential benefits in other metabolic disorders beyond NASH and dyslipidemia.

Conclusion

Resmetirom represents a promising therapeutic agent in the management of NASH and dyslipidemia, with its liver-targeted mechanism offering a novel approach to these challenging conditions. Continued research and clinical trials will determine its place in future treatment paradigms.

Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology